Australia  

Celebrating 10 Years of Trusted News Discovery
One News Page
> >

Imugene begins manufacture of its innovative cancer vaccine for trials

Proactive Investors Sunday, 23 September 2018
Imugene Limited (ASX:IMU) has formally commenced cGMP (current good manufacturing practice) manufacture of the clinical batch of its cancer vaccine KEY-Vaxx. The cGMP batch is part of the pre-clinical development for the proposed PD-1 phase I clinical trial to be conducted in 2019. AmbioPharm Inc, a US-based peptide manufacturing company has been appointed to manufacture the vaccine. We've commenced cGMP manufacturing of the clinical batch of cancer vaccine KEY-Vaxx for the proposed Phase 1 PD-1 clinical trial, after successfully completing pilot studies. AmbioPharm Inc. (APi), a US-based cGMP manufacturer has been appointed $IMU #ASX https://t.co/xL390CKopH pic.twitter.com/YVOYROEtbZ — Imugene Ltd (@TeamImugene) September 20, 2018 KEY-Vaxx is a B-cell peptide cancer vaccine which aims to induce the body to produce polyclonal antibodies that block PD-1 signalling, and potentially produce an anticancer effect similar to Keytruda, Opdivo and the other immune checkpoint inhibitor monoclonal antibodies that are transforming the treatment of a range of cancers. KEY-Vaxx has shown potential in preclinical studies, outperforming an industry-standard antibody in a mouse model of HER2+ colorectal cancer. New provisional patent The protection of Imugene’s global position in PD-1 B-cell cancer vaccines has been strengthened with the filing of a new provisional patent in Australia titled “A vaccine composition and uses thereof”. READ: Imugene signs exclusive, world-widelicence for cancer vaccine Imugene managing director Leslie Chong said: “Maintaining and strengthening our already strong international intellectual property position is a key area of focus in maintaining the competitive advantage of KEY-Vaxx and any future improvements, vaccine formulations and clinical uses. “We are extremely pleased with the progress made from our expert scientific team.”
0
shares
ShareTweetSavePostSend
 
Credit: Seeker - Published < > Embed
News video: What Happens When CRISPR Backfires?

What Happens When CRISPR Backfires? 03:26

Ever since it was introduced in 2013, CRISPR has been touted as a promising technology for treating inherited disorders, cancer, and other diseases with no current treatment options. Teams of researchers had been hoping to begin human trials in 2018, but none of those trials have taken place yet with...

You Might Like


Recent related videos from verified sources

Prostate Cancer Treatment Linked to Dementia [Video]Prostate Cancer Treatment Linked to Dementia

Prostate Cancer Treatment Linked to Dementia Research has found that androgen deprivation therapy, a prostate cancer drug treatment, is linked to dementia and Alzheimer’s. The study, conducted by..

Credit: Wibbitz Studio     Duration: 00:55Published

Never Too Young! More Young People Are Being Diagnosed With Colorectal Cancer [Video]Never Too Young! More Young People Are Being Diagnosed With Colorectal Cancer

Colorectal cancer is steadily on the rise in people younger than 50! According to the Colorectal Cancer Alliance, this type of cancer is now the third most common in the United States, claiming the..

Credit: Veuer     Duration: 01:13Published

Skin cancer is the most common cancer type in Colorado [Video]Skin cancer is the most common cancer type in Colorado

It’s summer now, and we may be tempted to lay out in the sun, soak up some rays and enjoy the season. However, living in Colorado poses a significant risk to our skin and eyes. Colorado’s elevation..

Credit: Rumble     Duration: 02:53Published

Researchers Testing New Method That Could Potentially Help Treat Pancreatic Cancer [Video]Researchers Testing New Method That Could Potentially Help Treat Pancreatic Cancer

For people diagnosed with pancreatic cancer, the prognosis is often dismal.

Credit: CBS4 Miami     Duration: 01:58Published


Other recent news in Business

Who is BORIS JOHNSON, the man tipped to be the UK's next prime minister?Two ARRESTED after climbing Sydney tower
Environmentally friendly: One News Page is hosted on servers powered solely by renewable energy
© 2019 One News Page Ltd. All Rights Reserved.
About us  |  Contact us  |  Disclaimer  |  Press Room  |  Terms & Conditions  |  Content Accreditation
 RSS  |  News for my Website  |  Free news search widget  |  In the News  |  DMCA / Content Removal  |  Privacy & Data Protection Policy
How are we doing? FeedbackSend us your feedback  |   LIKE us on Facebook   FOLLOW us on Twitter  •  FOLLOW us on Pinterest
One News® is a registered trademark of One News Page Ltd.